KU Cancer Center-invented drug could eliminate need for bladder removal

CicloMed LLC has expanded a clinical trial for an anti-cancer drug that could potentially transform the treatment of bladder cancer. Researchers at the University of Kansas Cancer Center and its Institute for Advancing Medical Innovation (IAMI) first discovered the treatment several years ago. Now, the drug is licensed out to CicloMed, a Kansas City-based biotechnology company formed by IAMI and Kansas City venture capital firm BioNovus Innovations LLC. Fosciclopirox is set to become the first…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Bladder cancer is the most common malignant tumor of the urinary system, and it has high incidence, high degree of malignancy, and easy recurrence after surgery. The etiology and pathogenesis of bladder cancer are not fully understood, but more and more studies have shown that its development may be regulated by some core molecules. To identify key molecules in bladder cancer, we constructed a three-layer network by merging lncRNA-miRNA regulatory network, miRNA-mRNA regulatory network, and lncRNA-mRNA coexpression network, and further analyzed the topology attributes of the network including the degree, betweenness centra...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Condition:   Urinary Bladder Neoplasms Interventions:   Drug: Pembrolizumab;   Radiation: Conventional Radiotherapy (Bladder only);   Radiation: Conventional Radiotherapy (Bladder and pelvic nodes);   Radiation: Hypofractionated Radiotherapy (Bladder only);   Drug: Cisplatin;   Drug: Fluorouracil (5-FU);   Drug: Mitomycin C (MMC);   Dru g: Gemcitabine;   Drug: Placebo to Pembrolizumab Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(Vanderbilt University Medical Center) A five-year follow-up study of more than 2,000 US men who received prostate cancer treatment is creating a road map for future patients regarding long-term bowel, bladder and sexual function in order to clarify expectations and enable men to make informed choices about care.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Recent NICE guidance says there is limited evidence for the efficacy of transurethral laser ablation for recurrent non ‐muscle invasive bladder cancer and that ‘special arrangements’ need to be in place if it is to be offered to patients. Here the authors consider the advantages and drawbacks of the treatment.
Source: Trends in Urology and Men's Health - Category: Urology & Nephrology Authors: Tags: NICE guidance Source Type: research
ConclusionsClosure of VVF is a significant challenge, with an initial success rate of 20% and an overall success rate of only 25%. Seventy percent required primary or secondary urinary diversion. Vaginal surgery was utilised in the majority to try to avoid a hostile pelvis, but the surgical approach should be tailored to individual circumstances.
Source: International Urogynecology Journal - Category: OBGYN Source Type: research
Authors: Mehta S, Farnia B, de la Zerda A, Rahimi R, Wolfson A, Portelance L Abstract Purpose: Smit sleeves are used to facilitate insertion of the intrauterine tandem during brachytherapy for cervical cancer. When a tandem and ovoids system is used the base of the Smit sleeve displaces the ovoids distally. The dosimetric impact of this displacement is not known. Herein we performed a dosimetric analysis to quantify this impact on the integral dose and dose delivered to the organs at risk (OARs). Material and methods: Eleven high-dose-rate brachytherapy plans in which a Smit sleeve was used with a tandem and ov...
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
Conclusions: The aim of the present paper was to produce a protocol consisting in intervention that could improve the internal serendipity and emotional state of patients who underwent HDR-IRT. PMID: 31969908 [PubMed]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
Conclusion: The use of RT may be an alternative option in well selected patients with limited disease who are considered unfit for systemic chemotherapy and RC. Future research should focus on improving patient selection and assess the quality-of-life as well as the need for reintervention in patients treated with RT. PMID: 31975654 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
Publication date: April 2020Source: Biomedicine &Pharmacotherapy, Volume 124Author(s): Yong Zhou, Bo Tian, Jinming Tang, Jie Wu, Hui Wang, Zhining Wu, Xu Li, Desong Yang, Baihua Zhang, Yuhang Xiao, Ying Wang, Junliang Ma, Wenxiang Wang, Min SuAbstractLong noncoding RNAs (lncRNAs) are a group of RNAs that lack protein-coding ability, with lengths greater than 200 nucleotides. Increasing evidence has indicated that they mediate multiple physiological and pathological processes by regulating gene expression at the epigenetic, transcriptional, post-transcriptional, and translational levels. The deregulation of lncRNAs was ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Biotechnology | Bladder Cancer | Cancer | Cancer & Oncology | Clinical Trials | Health Management | Venture Capital